Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study.
Maris M, Salles G, Kim WS, Kim TM, Lyons RM, Arellano M, Karmali R, Schiller G, Cull E, Abboud CN, Batlevi C, Kagiampakis I, Rebelatto MC, Lee Y, Kirby LC, Wang F, Bothos J, Townsley DM, Fathi AT, Ribrag V. Maris M, et al. Among authors: bothos j. Target Oncol. 2024 May;19(3):321-332. doi: 10.1007/s11523-024-01054-z. Epub 2024 Apr 29. Target Oncol. 2024. PMID: 38683495 Free PMC article. Clinical Trial.
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer.
Herbst RS, Majem M, Barlesi F, Carcereny E, Chu Q, Monnet I, Sanchez-Hernandez A, Dakhil S, Camidge DR, Winzer L, Soo-Hoo Y, Cooper ZA, Kumar R, Bothos J, Aggarwal C, Martinez-Marti A. Herbst RS, et al. Among authors: bothos j. J Clin Oncol. 2022 Oct 10;40(29):3383-3393. doi: 10.1200/JCO.22.00227. Epub 2022 Apr 22. J Clin Oncol. 2022. PMID: 35452273 Clinical Trial.
Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody-Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide.
de Bono JS, Fleming MT, Wang JS, Cathomas R, Miralles MS, Bothos J, Hinrichs MJ, Zhang Q, He P, Williams M, Rosenbaum AI, Liang M, Vashisht K, Cho S, Martinez P, Petrylak DP. de Bono JS, et al. Among authors: bothos j. Clin Cancer Res. 2021 Jul 1;27(13):3602-3609. doi: 10.1158/1078-0432.CCR-20-4528. Epub 2021 Apr 1. Clin Cancer Res. 2021. PMID: 33795255 Clinical Trial.
Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
Dreyling M, Jurczak W, Jerkeman M, Silva RS, Rusconi C, Trneny M, Offner F, Caballero D, Joao C, Witzens-Harig M, Hess G, Bence-Bruckler I, Cho SG, Bothos J, Goldberg JD, Enny C, Traina S, Balasubramanian S, Bandyopadhyay N, Sun S, Vermeulen J, Rizo A, Rule S. Dreyling M, et al. Among authors: bothos j. Lancet. 2016 Feb 20;387(10020):770-8. doi: 10.1016/S0140-6736(15)00667-4. Epub 2015 Dec 7. Lancet. 2016. PMID: 26673811 Clinical Trial.
Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies.
Salgia R, Patel P, Bothos J, Yu W, Eppler S, Hegde P, Bai S, Kaur S, Nijem I, Catenacci DV, Peterson A, Ratain MJ, Polite B, Mehnert JM, Moss RA. Salgia R, et al. Among authors: bothos j. Clin Cancer Res. 2014 Mar 15;20(6):1666-75. doi: 10.1158/1078-0432.CCR-13-2070. Epub 2014 Feb 3. Clin Cancer Res. 2014. PMID: 24493831 Clinical Trial.
Population pharmacokinetic analysis from phase I and phase II studies of the humanized monovalent antibody, onartuzumab (MetMAb), in patients with advanced solid tumors.
Xin Y, Jin D, Eppler S, Damico-Beyer LA, Joshi A, Davis JD, Kaur S, Nijem I, Bothos J, Peterson A, Patel P, Bai S. Xin Y, et al. Among authors: bothos j. J Clin Pharmacol. 2013 Nov;53(11):1103-11. doi: 10.1002/jcph.148. Epub 2013 Aug 7. J Clin Pharmacol. 2013. PMID: 23922054 Clinical Trial.
Human LATS1 is a mitotic exit network kinase.
Bothos J, Tuttle RL, Ottey M, Luca FC, Halazonetis TD. Bothos J, et al. Cancer Res. 2005 Aug 1;65(15):6568-75. doi: 10.1158/0008-5472.CAN-05-0862. Cancer Res. 2005. PMID: 16061636
12 results